TRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges

被引：129

作者：

Bellail, Anita C. ^{[1
]}

Qi, Ling ^{[1
]}

Mulligan, Patrick ^{[1
]}

Chhabra, Vaninder ^{[2
]}

Hao, Chunhai ^{[1
]}

机构：

[1] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA

[2] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA USA

来源：

REVIEWS ON RECENT CLINICAL TRIALS | 2009年 / 4卷 / 01期

基金：

加拿大健康研究院;

关键词：

Apoptosis; cancer; death receptor; monoclonal antibody; TRAIL;

D O I：

10.2174/157488709787047530

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is normally expressed in the human immune system and plays a critical role in antitumor immunity. TRAIL interacts with the death receptors, DR4 and DR5, and activates intracellular apoptotic pathway in cancer cells. This discovery has resulted in a rapid development of cancer therapeutic agents that can activate this apoptotic pathway. These therapeutic agents include recombinant human TRAIL (rhTRAIL) and its agonistic monoclonal antibody (MAb) against DR4 and DR5. Phase I trials have established the safety and tolerability of these TRAIL agonists in patients. Phase II trials are currently evaluating the therapeutic efficacy of TRAIL agonists as single agents or in combination with established cancer therapeutics. This review outlines the advances and the challenges in the development of these TRAIL agonists as effective clinical cancer therapeutics.

引用

页码：34 / 41

页数：8

共 116 条

[1] Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5 [J].

Adams, C. ;

Totpal, K. ;

Lawrence, D. ;

Marsters, S. ;

Pitti, R. ;

Yee, S. ;

Ross, S. ;

Deforge, L. ;

Koeppen, H. ;

Sagolla, M. ;

Compaan, D. ;

Lowman, H. ;

Hymowitz, S. ;

Ashkenazi, A. .

CELL DEATH AND DIFFERENTIATION, 2008, 15 (04) :751-761

[2]

Altieri Dario C, 2003, Methods Mol Biol, V223, P533

[3]

Asakuma J, 2003, CANCER RES, V63, P1365

[4] Safety and antitumor activity of recombinant soluble Apo2 ligand [J].

Ashkenazi, A ;

Pai, RC ;

Fong, S ;

Leung, S ;

Lawrence, DA ;

Masters, SA ;

Blackie, C ;

Chang, L ;

McMurtrey, AE ;

Hebert, A ;

DeForge, L ;

Koumenis, IL ;

Lewis, D ;

Harris, L ;

Bussiere, J ;

Koeppen, H ;

Shahrokh, Z ;

Schwall, RH .

JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162

[5] Targeting death and decoy receptors of the tumour-necrosis factor superfamily [J].

Ashkenazi, A .

NATURE REVIEWS CANCER, 2002, 2 (06) :420-430

[6] Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL) [J].

Ashkenazi, Avi ;

Holland, Pamela ;

Eckhardt, S. Gail .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) :3621-3630

[7] In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs [J].

Ashley, D. M. ;

Riffkin, C. D. ;

Lovric, M. M. ;

Mikeska, T. ;

Dobrovic, A. ;

Maxwell, J. A. ;

Friedman, H. S. ;

Drummond, K. J. ;

Kaye, A. H. ;

Gan, H. K. ;

Johns, T. G. ;

Hawkins, C. J. .

BRITISH JOURNAL OF CANCER, 2008, 99 (02) :294-304

[8] Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding [J].

Bin, Lianghua ;

Thorburn, Jacqueline ;

Thomas, Lance R. ;

Clark, Peter E. ;

Humphreys, Robin ;

Thorburn, Andrew .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (38) :28189-28194

[9] TRAIL receptor-2 signals apoptosis through FADD and caspase-8 [J].

Bodmer, JL ;

Holler, N ;

Reynard, S ;

Vinciguerra, P ;

Schneider, P ;

Juo, P ;

Blenis, J ;

Tschopp, J .

NATURE CELL BIOLOGY, 2000, 2 (04) :241-243

[10] 2.8 Å resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity [J].

Cha, SS ;

Kim, MS ;

Choi, YH ;

Sung, BJ ;

Shin, NK ;

Shin, HC ;

Sung, YC ;

Oh, BH .

IMMUNITY, 1999, 11 (02) :253-261

← 1 2 3 4 5 6 7 8 9 10 →